Insilico expands Tenacia CNS collaboration in $94.75M deal
CURRENT BRIEF VERSION: Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven central nervous system drug discovery collaboration, adding a second program and lifting the deal’s potential value to as much as $94.75 million. The March 26, 2026 announcement builds on the companies’ initial March 3, 2025 partnership, which paired Insilico’s Pharma.AI platform with Tenacia’s CNS biology and development capabilities to design blood-brain barrier-penetrant small-molecule inhibitors for neurological disease. Under the new agreement, the companies said they’ll use generative AI to develop an additional candidate with defined properties and advance it to the preclinical candidate stage, with Insilico eligible for near-term and milestone payments. (barchart.com)
Why it matters: For veterinary professionals, this isn’t an animal health deal, but it’s another sign that AI-enabled discovery platforms are gaining commercial traction in hard-to-treat disease areas where pharmacology and delivery are major barriers. CNS drug development is especially challenging because compounds must cross the blood-brain barrier, and Insilico has increasingly highlighted that capability across its pipeline, including its brain-penetrant NLRP3 program ISM8969, which received FDA IND clearance in January 2026. The company has also been broadening its partnership model, including a much larger March 2026 multi-program collaboration with Eli Lilly reportedly worth up to about $2.75 billion, with $115 million upfront, exclusive global rights for Lilly to certain preclinical oral candidates in select indications, and additional AI-enabled R&D programs on Lilly-selected targets. (barchart.com; PharmaShots)
What to watch: Watch for whether this expanded collaboration produces a named preclinical candidate, and whether Insilico continues to translate platform deals into clinical-stage CNS assets over the next 12 to 24 months. Its ability to turn smaller target-focused partnerships like Tenacia into tangible assets, while also servicing large multi-program alliances such as Lilly, will be an important test of how scalable the model really is. (barchart.com; PharmaShots)